

Nader El-Mallawany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/533610/publications.pdf>

Version: 2024-02-01

47
papers

942
citations

471509

17
h-index

477307

29
g-index

49
all docs

49
docs citations

49
times ranked

1193
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. <i>Blood</i> , 2011, 117, 5835-5849.	1.4	241
2	Clinical characteristics and outcomes of HIV-infected children diagnosed with kaposi sarcoma in Malawi and Botswana. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1274-1280.	1.5	44
3	Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 599-604.	27.6	40
4	Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes. <i>British Journal of Haematology</i> , 2022, 196, 31-44.	2.5	36
5	Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. <i>International Journal of Cancer</i> , 2017, 140, 2509-2516.	5.1	35
6	Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. <i>British Journal of Haematology</i> , 2016, 173, 705-712.	2.5	33
7	Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26302.	1.5	33
8	Adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 637-650.	2.5	30
9	Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0153335.	2.5	27
10	Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. <i>Pediatric Health, Medicine and Therapeutics</i> , 2018, Volume 9, 35-46.	1.6	26
11	Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. <i>Supportive Care in Cancer</i> , 2018, 26, 967-973.	2.2	23
12	Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. <i>Blood Advances</i> , 2020, 4, 4007-4019.	5.2	23
13	Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. <i>Blood Cancer Journal</i> , 2012, 2, e65-e65.	6.2	22
14	KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma: Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. <i>International Journal of Cancer</i> , 2019, 144, 110-116.	5.1	21
15	Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27353.	1.5	19
16	A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27798.	1.5	19
17	Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 113-23.	0.3	18
18	Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. <i>Blood Advances</i> , 2019, 3, 612-620.	5.2	17

#	ARTICLE	IF	CITATIONS
19	Spectrum of Childhood Epstein-Barr Virus-associated T-Cell Proliferations and Bone Marrow Findings. <i>Pediatric and Developmental Pathology</i> , 2011, 14, 28-37.	1.0	16
20	Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26370.	1.5	16
21	Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, Malawi. <i>Global Pediatric Health</i> , 2017, 4, 2333794X1771583.	0.7	16
22	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2017, 177, 601-611.	2.5	15
23	Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	15
24	Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma. <i>European Journal of Cancer</i> , 2015, 51, 92-100.	2.8	14
25	Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. <i>Clinical Infectious Diseases</i> , 2017, 64, 818-819.	5.8	14
26	Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. <i>Infectious Agents and Cancer</i> , 2018, 13, 33.	2.6	14
27	Identifying opportunities to bridge disparity gaps in curing childhood cancer in Malawi: Malignancies with excellent curative potential account for the majority of diagnoses. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 261-274.	0.8	12
28	Checkmate for EBV-HLH. <i>Blood</i> , 2020, 135, 782-784.	1.4	11
29	Tumoral Bacillary Angiomatosis in a Child With Human Immunodeficiency Virus. <i>JAMA Dermatology</i> , 2014, 150, 1015.	4.1	10
30	Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi. <i>Clinical Infectious Diseases</i> , 2019, 69, 2022-2025.	5.8	9
31	Humoral and Cellular Immunotherapy in ALL in Children, Adolescents, and Young Adults. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S6-S13.	0.4	8
32	Navigating the heterogeneous landscape of pediatric Kaposi sarcoma. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 749-758.	5.9	7
33	Association between Antiretroviral Therapy and Cancers among Children Living with HIV in Sub-Saharan Africa. <i>Cancers</i> , 2021, 13, 1379.	3.7	7
34	Lessons From Pediatric HIV: A Case for Curative Intent in Pediatric Cancer in LMICs. <i>Pediatrics</i> , 2017, 140, e20170525.	2.1	6
35	Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 141-148.	2.1	6
36	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3603.	3.7	6

#	ARTICLE	IF	CITATIONS
37	Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 758-766.	2.9	6
38	Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment. <i>British Journal of Haematology</i> , 2018, 181, 853-854.	2.5	5
39	Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania. <i>Children</i> , 2021, 8, 275.	1.5	5
40	Clinical characteristics and successful treatment outcomes of children and adolescents with Kaposi sarcoma in Southwestern Tanzania. <i>Pediatric Hematology and Oncology</i> , 2021, , 1-20.	0.8	4
41	Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB) Tj ETQq1 1 0.784314 rgBT ₄ /Overlook 2016. 34. 10534-10534.	1.6	4
42	Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries. <i>International Journal of STD and AIDS</i> , 2020, 31, 724-734.	1.1	3
43	Long-term outcomes for children and adolescents with Kaposi sarcoma. <i>HIV Medicine</i> , 2021, 23, 197.	2.2	3
44	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
45	Childhood and Adolescence Non-Hodgkin Lymphomas in Low- and Middle-Income Countries. , 2019, , 337-351.		0
46	Immunodeficiency-Associated Hematological Malignancies. , 2012, , 363-388.		0
47	T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science. , 2013, , 179-216.		0